Table 3.
Laboratory data
| Total | Antecedent infectious agents | ||||
|---|---|---|---|---|---|
| H. influenzae | C. jejuni | CMV | None identified | ||
| Number | 70 | 15 | 10 | 6 | 39 |
| IgG Abs against | |||||
| GQ1b | 65 (93%) | 14 (93%) | 10 (100%) | 5 (83%) | 36 (92%) |
| GT1a | 67 (96%) | 15 (100%) | 10 (100%) | 5 (83%) | 37 (95%) |
| GM1 | 5 (7.1%) | 0 | 2 (20%) | 1 (17%) | 2 (5.1%) |
| GD1a | 5 (7.1%) | 0 | 2 (20%) | 0 | 3 (7.7%) |
| GD1b | 14 (20%) | 3 (20%) | 1 (10%) | 2 (33%) | 7 (18%) |
| GM1/GT1a complex | 67 (96%) | 15 (100%) | 10 (100%) | 5 (83%) | 37 (95%) |
| GM1/GD1a complex | 9 (13%) | 1 (6.7%) | 2 (20%) | 2 (33%) | 3 (7.7%) |
| IgG subclass of anti-GQ1b Absa | |||||
| Only IgG1 | 29/65 (45%) | 8 (53%) | 6/9 (67%) | 2 (33%) | 14/36 (39%) |
| Only IgG3 | 27/65 (42%) | 4 (27%) | 3/9 (33%) | 4 (67%) | 16/36 (44%) |
| Both IgG1 + IgG3 | 9/65 (14%) | 3 (20%) | 0/9 | 0 | 6/36 (17%) |
| Cerebrospinal fluid | |||||
| Increased protein conc | 23/54 (43%) | 4 (27%) | 3/7 (43%) | 2/5 (40%) | 13/27 (48%) |
| Increased cell count | 5/54 (9.3%) | 2 (13%) | 0/7 | 0/5 | 2/27 (7.4%) |
CMV cytomegalovirus, Abs antibodies, conc concentration
aAnti-GT1a antibodies in cases of negative anti-GQ1b antibodies